Back

Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy (DAPT) Study

30 August 2016 (16:30 - 16:45)
Organised by:
Congress Presentation Part of: Clinical Trial Update Platelet therapy Adjunctive medical therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Charles Resor

Brigham and Women's Hospital, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Prevention of First Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54
Doctor M. Bonaca (Aurora, US)
Slides Video
Presentation thumbnail
The Italic/Italic Plus Trial
Professor M. Gilard (Brest, FR)
Slides Video
Presentation thumbnail
PCI for Elderly patients at High Bleeding Risk. A substudy of the LEADERS FREE trial
Doctor M. Morice (Massy, FR)
Slides Video
Presentation thumbnail
Ten-year outcomes of first-generation drug-eluting stents results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization (SIRTAX) VERY LATE Trial
Professor L. Raber (Bern, CH)
Slides Video
Presentation thumbnail
Ad-hoc versus non-ad-hoc percutaneous coronary intervention strategies in patients with stable coronary artery disease.
Doctor T. Toyota (Kobe, JP)
Slides Video

Access the full session

Session thumbnail
Clinical Trial Update Platelet therapy

The Event

Event poster

ESC Congress 2016

30 August 2016 16:30 CET
You may be interested in
thumbnail
Congress Session
Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more
28 August 2023
thumbnail
Congress Presentation
Outcomes of dual antiplatelet therapy in combination with direct oral anticoagulants in patients with acute coronary syndrome: a meta-analysis
28 August 2022
thumbnail
Congress Presentation
Pretreatment with dual antiplatelet therapy in acute myocardial infarction
30 August 2024
thumbnail
Webinar
Balancing stroke and bleeding risks in patients with AF and concomitant coronary artery disease, malignancy, chronic kidney disease, or frailty
10 November 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources